Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· January 14, 2026

Stocks Retreat as Big Tech Falters

View original at nasdaq.com
Stocks Retreat as Big Tech Falters The S&P 500 Index ($SPX) (SPY) today is down -0.96%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.57%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.53%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Upgraded CNH Industrial to buy from neutral with a price target of $13

    80% confidence
  • Higher potash demand justifies raising Mosaic price target to $35 from $33

    80% confidence
  • S&P earnings growth is expected to climb by 8.4% in Q4

    80% confidence
  • Downgraded Rivian to sell from neutral with a price target of $15

    80% confidence
  • President Trump urged Iranians to continue protests against the government and said he would act accordingly once he gets a sense for how many demonstrators have been killed

    80% confidence
  • The US economy is showing resilience and he doesn't see the impetus for the Fed to cut interest rates this month

    80% confidence
  • Justice Department was threatening a criminal indictment tied to his June testimony on Fed headquarters renovations, in retaliation for the Fed's refusal to go along with President Trump's calls for lower interest rates

    80% confidence
  • Upgraded Fabrinet to overweight from equal weight with a price target of $537

    80% confidence
  • Eurozone inflation remains in a good place, though global uncertainty is weighing on the economy

    80% confidence
  • Q4 earnings excluding Magnificent Seven are expected to increase by 4.6%

    80% confidence
  • She sees inflation moderating, the labor market stabilizing, and growth coming in around 2% this year, with some modest further adjustments to the funds rate likely appropriate later in the year

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com